Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, ...
The National Testing Agency (NTA) has issued the subject wise NEET 2026 syllabus on this website soon after the NMC released ...
Morning Brief host Julie Hyman and Yahoo Finance Markets and Data Editor Jared Blikre track several of Friday's top trending ...
Q2 2026 Earnings Call Transcript January 8, 2026 Aehr Test Systems beats earnings expectations. Reported EPS is $-0.04, ...
Investor's Business Daily on MSN
Dow Jones futures: It's a broad, strong rally, do your stocks reflect that? JPMorgan, Goldman, Delta, Taiwan Semi loom
The stock market is at highs with JPMorgan, Goldman, Taiwan Semi and Delta earnings due. Two huge conferences, inflation data ...
Edge devices across multiple applications share common attack vectors. Security functionality must be designed in from the ...
14h
Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, ...
The presented findings are important for the field of cell-cycle control. They provide new insights into the origin of cell size variability in budding yeast. The strength of evidence is solid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback